tiprankstipranks
Trending News
More News >
Enlivex Therapeutics (ENLV)
:ENLV
Advertisement

Enlivex (ENLV) Price & Analysis

Compare
430 Followers

ENLV Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Efficacy DataEnlivex has reported positive interim efficacy data for patients in Phase 1 with significant improvements and no safety issues.
Intellectual PropertyChinese patent claims allowed for Allocetra in osteoarthritis treatment, providing added protection through at least 2040.
Bears Say
Clinical TrialThe Phase 2 trial will rigorously evaluate joint-pain and function with a double-blind, randomized, placebo-controlled design.

Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.04%<0.01%99.34%
Insiders
<0.01% Other Institutional Investors
99.34% Public Companies and
Individual Investors

ENLV FAQ

What was Enlivex Therapeutics’s price range in the past 12 months?
Enlivex Therapeutics lowest stock price was $0.81 and its highest was $1.76 in the past 12 months.
    What is Enlivex Therapeutics’s market cap?
    Enlivex Therapeutics’s market cap is $27.90M.
      When is Enlivex Therapeutics’s upcoming earnings report date?
      Enlivex Therapeutics’s upcoming earnings report date is May 23, 2025 which is 64 days ago.
        How were Enlivex Therapeutics’s earnings last quarter?
        Enlivex Therapeutics released its earnings results on May 24, 2024. The company reported -$0.25 earnings per share for the quarter, the consensus estimate of -$0.25 by $0.
          Is Enlivex Therapeutics overvalued?
          According to Wall Street analysts Enlivex Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Enlivex Therapeutics pay dividends?
            Enlivex Therapeutics does not currently pay dividends.
            What is Enlivex Therapeutics’s EPS estimate?
            Enlivex Therapeutics’s EPS estimate is -0.15.
              How many shares outstanding does Enlivex Therapeutics have?
              Enlivex Therapeutics has 23,849,936 shares outstanding.
                What happened to Enlivex Therapeutics’s price movement after its last earnings report?
                Enlivex Therapeutics reported an EPS of -$0.25 in its last earnings report, expectations of -$0.25. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of Enlivex Therapeutics?
                  Currently, no hedge funds are holding shares in ENLV

                  Company Description

                  Enlivex Therapeutics

                  Enlivex (NASDAQ: ENLV) is a clinical-stage biopharmaceutical company engaged in the development of innovative immunotherapy treatments. The company is primarily focused on discovering and developing cell therapies designed to treat life-threatening conditions resulting from the overreaction of the immune system, such as sepsis and cancer. Enlivex's core product candidate is Allocetra, a cell therapy intended to modulate immune system responses and restore balance to the immune system.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Cel-Sci
                  Pulmatrix
                  Ovid Therapeutics
                  ImmunoPrecise Antibodies
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis